RxDoctor Payments Data

Jennifer Giddens

Family · Boaz, ALNPI 1396294229

Payments from drug & device makers

$8,604in general payments, 2019–2025

Across 568 payments — averaging $15.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$879
  • Novo Nordisk$582
  • Amgen$576
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$531
  • AstraZeneca$392
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$8,604100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,604 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$39,360
Medicare patients
205
Services billed
2,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$89,444
FarxigaDapagliflozin Propanediol74$57,445
MounjaroTirzepatide41$44,790
TrulicityDulaglutide38$42,509
JardianceEmpagliflozin46$36,619
EliquisApixaban46$35,624
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$34,812
LinzessLinaclotide39$27,123
RexultiBrexpiprazole14$19,829
XareltoRivaroxaban31$16,519
Spiriva RespimatTiotropium Bromide15$11,791
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$10,510
Bydureon BciseExenatide Microspheres12$9,592
MyrbetriqMirabegron13$9,448
Albuterol Sulfate HfaAlbuterol Sulfate320$8,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$582$89,44481 claims
Lilly USA, LLCMounjaro, Trulicity$297$87,29979 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$392$75,051117 claims
Boehringer IngelheimJardiance, Spiriva Respimat$90$48,41061 claims
GSKTrelegy Ellipta, Anoro Ellipta$879$42,79670 claims
PfizerEliquis$201$35,62446 claims
AbbVieLinzess$1,546$27,12339 claims
Otsuka America Pharmaceutical, Inc.Rexulti$261$19,82914 claims
Johnson & JohnsonXarelto$40$16,51931 claims
Astellas Pharma US IncMyrbetriq$19$9,44813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.

Other family in Boaz

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →